RxDoctor Payments Data

Charles Cummings, DO

Family Medicine · Fall River, MANPI 1407811615

Payments from drug & device makers

$361in general payments, 2019–2025

Across 15 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$173
  • Astellas Pharma US Inc$77
  • Amarin Pharma, Inc.$48
  • Lilly USA, LLC$30
  • Boehringer Ingelheim$18
  • Sumitomo Pharma America, Inc.$16

What the payments were for

  • Food & beverage$29682%
  • Education$6518%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$361 in reported general payments places this provider in the 70th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$157,024
Medicare patients
275
Services billed
3,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$164,068
OzempicSemaglutide82$107,587
JardianceEmpagliflozin121$101,042
TrulicityDulaglutide46$73,786
MounjaroTirzepatide58$62,812
Synjardy XrEmpagliflozin/Metformin Hcl54$57,902
LinzessLinaclotide30$23,706
FarxigaDapagliflozin Propanediol21$21,176
JanuviaSitagliptin Phosphate19$19,679
SynjardyEmpagliflozin/Metformin Hcl29$17,685
EntrestoSacubitril/Valsartan20$17,522
MyrbetriqMirabegron26$15,564
VascepaIcosapent Ethyl39$13,349
Tresiba Flextouch U-100Insulin Degludec25$11,999
GemtesaVibegron17$9,683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Spiriva Respimat$18$182,836216 claims
PfizerEliquis$173$164,068199 claims
Lilly USA, LLCTrulicity, Mounjaro$30$136,599104 claims
Astellas Pharma US IncMyrbetriq$77$15,56426 claims
Sumitomo Pharma America, Inc.Gemtesa$16$9,68317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →